Sentinel Lymph Node in Non-Small Cell Lung Cancer: Assessment of Feasibility and Safety by Near-Infrared Fluorescence Imaging and Clinical Consequences.
Fiche publication
Date publication
décembre 2022
Journal
Journal of personalized medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GAUCHOTTE Guillaume
Tous les auteurs :
Stasiak F, Seitlinger J, Streit A, Wollbrett C, Piccoli J, Siat J, Gauchotte G, Renaud S
Lien Pubmed
Résumé
Occult micrometastases can be missed by routine pathological analysis. Mapping of the pulmonary lymphatic system by near-infrared (NIR) fluorescence imaging can identify the first lymph node relay. This sentinel lymph node (SLN) can be analyzed by immunohistochemistry (IHC), which may increase micrometastasis detection and improve staging. This study analyzed the feasibility and safety of identifying SLNs in thoracic surgery by NIR fluorescence imaging in non-small cell lung cancer (NSCLC). This was a prospective, observational, single-center study. Eighty adult patients with suspected localized stage NSCLC (IA1 to IIA) were included between December 2020 and May 2022. All patients received an intraoperative injection of indocyanine green (ICG) directly in the peri tumoural area or by electromagnetic navigational bronchoscopy (ENB). The SLN was then assessed using an infrared fluorescence camera. SLN was identified in 60 patients (75%). Among them, 36 SLNs associated with a primary lung tumor were analyzed by IHC. Four of them were invaded by micrometastases (11.1%). In the case of pN0 SLN, the rest of the lymphadenectomy was cancer free. The identification of SLNs in thoracic surgery by NIR fluorescence imaging seems to be a feasible technique for improving pathological staging.
Mots clés
electromagnetic navigation bronchoscopy, indocyanine green, lung tumors, near-infrared fluorescence, occult micrometastases, sentinel lymph node
Référence
J Pers Med. 2022 12 30;13(1):